Spikevax (elasomeran) / Moderna, Takeda - LARVOL DELTA

Febrile seizure risk following monovalent COVID-19 mRNA vaccination in US children aged 2-5 years. (PubMed, Vaccine) - "Among children aged 2-5 years, the analysis showed a small elevated incidence rate ratio of febrile seizures in the 0-1 days following the mRNA-1273 vaccination."

Journal • CNS Disorders • Epilepsy • Infectious Disease • Novel Coronavirus Disease

Morphological changes induced by buffer exchange during preparation of mRNA-lipid nanoparticles occur in a stepwise manner as pH is elevated. (PubMed, Mol Ther Methods Clin Dev) - "We compared LNPs formed by different ionizable lipids, including DLin-MC3-DMA, ALC-0315, and SM-102, used, respectively, in the Food and Drug Administration (FDA)-approved products, Onpattro, Comirnaty, and Spikevax. SAXS profiles showed that, when fully formed at the final pH of 7.4, MC3 and ALC-0315 LNPs had lost bilayer-like structures, which were present after particle formation at pH 4. In contrast, LNPs produced with 1,2-dioleyloxy-3-dimethylaminopropane (DODMA) and SM-102 retained some bilayer-like structures at pH 7.4."

Journal

From RNA to DNA: How Cargo Identity Reprograms Lipid Nanoparticle Architecture and Function. (PubMed, Adv Healthc Mater) - "Lipid nanoparticles (LNPs) have become the leading platform for delivering genetic material, gaining global recognition through the success of mRNA-based COVID-19 vaccines such as mRNA-1273 (SpikeVax, Moderna) and BNT162b2 (Comirnaty, BioNTech/Pfizer). By highlighting these unique physical and biological challenges, this review underscores the need to move beyond simply adapting RNA-based formulations. Instead, a cargo-informed design approach will be key to unlocking the full therapeutic potential of DNA-LNPs in next-generation gene delivery."

Journal • Review • Infectious Disease • Novel Coronavirus Disease

Temporal dynamics of SARS-CoV-2 antibodies and IgG subclasses following multiple doses and diverse COVID-19 vaccine combinations. (PubMed, Front Immunol) - "The present study investigated the humoral immune response in 331 participants between January 2021 and January 2023, who received mRNA (BNT162b2-BioNTech/Pfizer, mRNA-1273-Moderna), vector-based (ChAdOx1-S-AstraZeneca, Gam-COVID-Vac-Gamaleya Research Institute), inactivated virus (BBIBP-CorV-Sinopharm) vaccines, or a heterologous combination (ChAdOx1-S followed by mRNA), with all participants receiving an mRNA booster 6-8 months after primary vaccination. The IgG subclass response was more influenced by the type of vaccine used for the two-dose primary vaccination than by the mRNA vaccine used for boosting. Altogether, these findings underscore the importance of booster doses and provide valuable insight into the longevity and quality of humoral responses, including the durability and breadth of neutralizing antibodies, across different vaccination strategies."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

HIV patients with poor immune recovery show exhausted CD4+ stem cell memory cells and impaired COVID-19 vaccine response. (PubMed, Clin Immunol) - "In this study, we longitudinally analyzed T cell memory responses following mRNA-1273 vaccination in PWHIV...We identified a subset of PD-1+TIGIT+ CD4+ TSCM and TCM cells that phenotypically resemble CD8+ exhausted-like progenitors (TPEX) and are enriched in PWHIV with poor immune recovery. Modulation of the Wnt/mTORs pathway via GSK3β inhibition restored TCF-1 expression and partially rescued antigen responsiveness, highlighting a potential strategy to improve vaccine efficacy in PWHIV."

IO biomarker • Journal • Human Immunodeficiency Virus • Infectious Disease • Novel Coronavirus Disease • CD4 • CD8 • PD-1 • TIGIT

Risk factors of myocarditis and pericarditis following mRNA-1273 vaccination: a population-based case-cohort study in five VAC4EU European databases (ESCMID Global 2026) - No abstract available

Clinical • Cardiovascular • Inflammation

Phase 1/2 randomized, observer-blind clinical trial of a first-generation, mRNA-based vaccine against seasonal influenza and COVID-19 in healthy adults. (PubMed, Hum Vaccin Immunother) - P1/2 | "Systems serology analysis indicated that mRNA-1073 induced robust, balanced antibody responses with comparable immune profiles to mRNA-1010 + mRNA-1273. mRNA-1073 had an acceptable safety profile and elicited durable immune responses against all vaccine-matched influenza and SARS-CoV-2 strains, supporting ongoing evaluations of mRNA-based multicomponent vaccines that simultaneously protect against seasonal influenza and COVID-19 in a single dose.Registration: ClinicalTrials.gov identifier: NCT05375838 (https://clinicaltrials.gov/study/NCT05375838)."

Clinical • Journal • P1/2 data • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Efficacy and Safety of mRNA-Based COVID-19 Vaccines in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis. (PubMed, Vaccines (Basel)) - "SOTRs exhibit profound hypo responsiveness to COVID-19 vaccines; however, the extreme heterogeneity observed across studies necessitates a cautious interpretation of pooled seroconversion estimates. While the data indicates a significant dose-response relationship favoring an aggressive, multi-dose strategy, the apparent safety profile may reflect under-reporting and limited follow-up rather than confirmed safety equivalence. Rare but clinically critical outcomes, such as acute allograft rejection, remain inadequately characterized in the current literature. Consequently, while the prioritization of multi-dose regimens and hybrid immunity is supported to maximize protection, clinicians must recognize that individual responses remain highly variable, and the long-term immunological impact of repeated stimulation requires further standardized investigation."

Journal • Retrospective data • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Solid Organ Transplantation • Transplant Rejection • Transplantation

IgG4 Neutralization and Sustained Total IgG Fc-Effector Functions Following Repeated SARS-CoV-2 Vaccination with mRNA-1273. (PubMed, Infect Dis Ther) - P3 | "These findings suggest that elevated IgG4 responses did not antagonize overall Fc-mediated effector mechanisms, indicating that mRNA-1273 induces a multi-subclass antibody response that preserves antiviral functionality."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Tubulointerstitial nephritis with uveitis (TINU) syndrome following COVID-19 vaccination in an elderly patient: a case report. (PubMed, CEN Case Rep) - "A case of tubulointerstitial nephritis and uveitis (TINU) syndrome in a 70-year-old man following administration of the third dose of the mRNA-1273 coronavirus disease 2019 (COVID-19) vaccine is reported...Due to progressive renal impairment, the patient received intravenous methylprednisolone pulse therapy (500 mg daily for three days), followed by oral prednisolone (40 mg daily), which was gradually tapered. Both renal function and ocular symptoms improved steadily. This case underscores a rare but important potential adverse event following COVID-19 vaccination, highlighting the need for awareness of immune-mediated complications such as TINU syndrome in the post-vaccination setting."

Journal • Anorexia • Dyslipidemia • Infectious Disease • Metabolic Disorders • Nephrology • Novel Coronavirus Disease • Ocular Inflammation • Ophthalmology • Pain • Renal Disease • Respiratory Diseases • Uveitis

Enhanced immune responses to mRNA compared with adenoviral vector COVID-19 vaccines during pregnancy: implications for pandemic preparedness. (PubMed, Vaccine) - P | "mRNA COVID-19 vaccination during pregnancy elicited more rapid and robust immune responses compared to AV vaccination. These findings suggest that mRNA vaccines may be preferable for emergency use during pregnancy and support their use in future maternal vaccine development and in pandemic preparedness recommendations."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD40LG

Evaluating the Effectiveness of 2024-2025 Seasonal mRNA-1273 Vaccination Against COVID-19-Related Hospitalizations and Medically Attended COVID-19 Among Adults Aged ≥ 18 years in the United States: An Observational Matched Cohort Study. (PubMed, Infect Dis Ther) - "The mRNA-1273 KP.2 vaccine demonstrated significant incremental effectiveness in preventing hospitalization with COVID-19 and medically-attended COVID-19 in adults during the 2024-2025 season to date. The VE was sustained with longer median follow up time. These findings support ongoing vaccination efforts to mitigate the public health impact of COVID-19."

Journal • Infectious Disease • Novel Coronavirus Disease

Loading of STING Agonist into Lipid Nanoparticles Boosts Dendritic Cell Activation. (PubMed, ACS Omega) - "Here, we explore the potential of FDA-approved lipid nanoparticles (LNPs), used in Spikevax COVID-19 vaccine, to increase the uptake of a cGAMP analog (cGsAsMP) to dendritic cells (DCs) and induce cell activation...When applied to this model, cGsAsMP LNPs successfully reprogram tumor-associated DCs toward an active state, thus emphasizing their potential for cancer immunotherapy. Overall, this work presents a novel and scalable approach utilizing LNPs to deliver cyclic dinucleotide-based STING agonists to counteract immune suppression in cancer."

Journal • Infectious Disease • Novel Coronavirus Disease • Oncology

COVID-19 vaccination and systemic autoimmune rheumatic diseases: No evidence of disproportionately increased reporting in VAERS. (PubMed, Semin Arthritis Rheum) - "In a large national pharmacovigilance dataset, COVID-19 vaccines were not associated with a disproportionate increase in reports of any SARD. These results support the favorable safety profile of COVID-19 vaccines with respect to autoimmune rheumatic events, while highlighting the value of ongoing post-marketing surveillance for rare immune-mediated reactions."

Journal • Giant Cell Arteritis • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Musculoskeletal Pain • Myositis • Novel Coronavirus Disease • Pain • Rheumatology • Scleroderma • Sjogren's Syndrome • Systemic Lupus Erythematosus • Systemic Sclerosis • Vasculitis

Systematic Review and Meta-Analysis of the Incidence of Myocarditis and Guillain-Barré Syndrome in Adolescents Receiving COVID-19 mRNA Vaccine. (PubMed, Cureus) - "Eligible studies included randomized controlled trials (RCTs), cohort studies, case-control studies, self-controlled case series, and pharmacovigilance database analyses reporting myocarditis or GBS outcomes in adolescents receiving BNT162b2 or mRNA-1273. Absolute risks remain low, and outcomes are generally favorable compared to SARS-CoV-2 infection. Continued surveillance and long-term follow-up are warranted."

Journal • Retrospective data • Review • Cardiovascular • Infectious Disease • Inflammation • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Antibody concentration and function following SARS-CoV-2 vaccination decrease with age in adults and children with Down syndrome. (PubMed, Vaccine) - P=N/A | "This is the first vaccine immunology study in DS including both children and adults. Although all participants showed a rise in antibody concentrations, decreased antibody concentrations and serum neutralization after primary and booster SARS-CoV-2 vaccination were seen in individuals with DS compared with HC. Vaccine response defects in DS were age dependent, increasing with age. Teenagers with DS had the highest antibody concentrations while children <12 years had significantly lower concentrations. Our findings highlight the need for a tailored, age-specific immunization strategy in DS."

Journal • Developmental Disorders • Genetic Disorders • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Signatures of Trained Immunity Following mRNA Vaccination: Differences Between mRNA-1273 and BNT162b2. (PubMed, J Clin Immunol) - "In conclusion, our study provides evidence that mRNA-1273, but not BNT162b2, induces immune responses consistent with the concept of trained immunity. These results highlight the potential for mRNA vaccine platforms to shape innate immunity, with implications for future vaccine design aimed at enhancing non-specific and specific protection against infectious diseases."

Journal • Infectious Disease • Novel Coronavirus Disease • CCL2 • IL6 • TNFA

New-Onset Vitiligo and Change in Disease Status Following COVID-19 Vaccination and COVID-19 Infection-An Online Survey. (PubMed, Australas J Dermatol) - "Among 114 respondents, over half reported no new-onset vitiligo or a change in vitiligo status following COVID-19 vaccination or infection; however, a sizeable minority reported worsening of vitiligo, smaller numbers reported new-onset disease, and few reported improvement. Larger studies are needed to clarify whether these associations are coincidental or reflect underlying pathological processes."

Journal • Dermatology • Immunology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Vitiligo

A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) (clinicaltrials.gov) - P4 | N=30000 | Recruiting | Sponsor: ModernaTX, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

DAN-COVID: Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19 (clinicaltrials.gov) - P4 | N=285000 | Recruiting | Sponsor: Tor Biering-Sørensen

New P4 trial • Infectious Disease • Novel Coronavirus Disease

Systematic analysis of COVID-19 mRNA vaccines using four orthogonal approaches demonstrates no excessive DNA impurities. (PubMed, NPJ Vaccines) - "Our results show that the quantity of residual DNA in all 15 analysed batches of Comirnaty and Spikevax vaccines is below approved limits and that it consists of small fragments originating from the template used to transcribe mRNA during vaccine production. We demonstrate that reliable mRNA vaccine analysis for DNA impurities requires rigorous application of well-controlled methods that minimise mutual interference of vaccine components."

Journal • Infectious Disease • Novel Coronavirus Disease

Association between sars-cov-2 infection, COVID-19 vaccines and immune thrombocytopenia in adults. a nationwide population-based study in France. (ASH 2025) - P=N/A | "Although such cases were expected to be sporadic, the possibility of an increased risk at thepopulation level remained uncertain to date.Therefore, we aimed to measure the association between COVID-19 vaccines overall and by type (mRNAvaccines: Comirnaty Pfizer - BNT162b2; Spikevax Moderna - mRNA-12773; and adenovirus-basedvaccines: Vaxzevria AstraZeneca -ChadOx-1-S, and JCovden Janssen AD26COV-2.S) and the occurrence ofITP at the nationwide scale in France. This nationwide population-based study using three different designs showed an associationbetween SARS-CoV-2 infection and ChadOx1-S vaccine with ITP occurrence, while no association wasfound for mRNA vaccines."

Clinical • Hematological Disorders • Immune Thrombocytopenic Purpura • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Thrombocytopenia • Thrombocytopenic Purpura

P108 Association between COVID-19 vaccines and bullous pemphigoid: a UK population-based study. (PubMed, Br J Dermatol) - "aORs were estimated for the general association between COVID-19 vaccines and BP; for products: the AstraZeneca, Pfizer and Spikevax vaccines; and for vaccine types: mRNA or vector...In conclusion, we did not find evidence of COVID-19 vaccines leading to an onset of BP. Our finding of a potential protective effect with three or more doses may reassure clinicians and people currently eligible to consider COVID-19 vaccination, and in particular provide evidence to discuss risks and benefits with vaccine-hesitant patients at risk of BP when considering COVID-19 vaccination."

Journal • Alzheimer's Disease • Bullous Pemphigoid • Cardiovascular • CNS Disorders • Dementia • Dermatology • Dermatopathology • Immunology • Infectious Disease • Movement Disorders • Novel Coronavirus Disease • Parkinson's Disease

Pityriasis rubra pilaris triggered by vaccination. (PubMed, Ital J Dermatol Venerol) - "In conclusion, PRP post-vaccination is rare and likely underdiagnosed, but recognizing the association is important to evaluate any new exposures to the trigger. A thorough patient history, including recent vaccinations, is crucial."

Journal • Dermatology • Infectious Disease • Measles • Mumps • Novel Coronavirus Disease • Pediatrics • Pertussis • Respiratory Diseases • Rubella • Tetanus

Inhibition of CXCL10 and IFN-γ ameliorates myocarditis in preclinical models of SARS-CoV-2 mRNA vaccination. (PubMed, Sci Transl Med) - "Through analysis of human plasma data and in vitro experiments with human macrophages and T cells, we identified increased C-X-C motif chemokine ligand 10 (CXCL10) and interferon-γ (IFN-γ) after exposure to BNT162b2 (Pfizer) or mRNA-1273 (Moderna). In mice exposed to these cytokines or receiving BNT162b2 vaccination, genistein treatment reduced cardiac injury markers and attenuated infiltration of neutrophils and macrophages into the heart. These findings implicate CXCL10-IFN-γ signaling as a contributor to myocardial injury in experimental models of mRNA vaccination and indicate that pharmacologic modulation, such as with genistein, may mitigate cytokine-driven injury."

Journal • Preclinical • Cardiovascular • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • CXCL10 • IFNG